Proteostasis Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• PTI-428

Phase 1 pipeline

• ethinyl estradiol and levonorgestrel · Other
  12.1 Mechanism of action COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
• PTI-801
• PTI-808

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Proteostasis Therapeutics, Inc. portfolio CI brief
• Proteostasis Therapeutics, Inc. pipeline updates RSS